AAAAAA

   
Results: 1-25 | 26-36 |
Results: 26-36/36
Ten-year clinical and angiographic follow-up of coronary wallstent
Authors: Carrie, D Elbaz, M Andrieu, M Cantie, P Fourcade, J Puel, J
Citation: D. Carrie et al., Ten-year clinical and angiographic follow-up of coronary wallstent, AM J CARD, 85(1), 2000, pp. 95
Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plusdidanosine combination therapy
Authors: Pellegrin, I Izopet, J Reynes, J Denayrolles, M Montes, B Pellegrin, JL Massip, P Puel, J Fleury, H Segondy, M
Citation: I. Pellegrin et al., Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plusdidanosine combination therapy, AIDS, 13(13), 1999, pp. 1705-1709
Using RT-PCR and bDNA assays to measure non-clade BHIV-1 subtype RNA
Authors: Pasquier, C Sandres, K Salama, G Puel, J Izopet, J
Citation: C. Pasquier et al., Using RT-PCR and bDNA assays to measure non-clade BHIV-1 subtype RNA, J VIROL MET, 81(1-2), 1999, pp. 123-129
Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
Authors: Izopet, J Bicart-See, A Pasquier, C Sandres, K Bonnet, E Marchou, B Puel, J Massip, P
Citation: J. Izopet et al., Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine, J MED VIROL, 59(4), 1999, pp. 507-511
Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit
Authors: Izopet, J Pasquier, C Sandres, K Puel, J Rostaing, L
Citation: J. Izopet et al., Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit, J MED VIROL, 58(2), 1999, pp. 139-144
Intermittent selection pressure with zidovudine plus zalcitabine treatmentreduces the emergence in vivo of zidovudine resistance HIV mutations
Authors: Izopet, J Sailler, L Sandres, K Pasquier, C Bonnet, E Aquilina, C Puel, J Massip, P Marchou, B
Citation: J. Izopet et al., Intermittent selection pressure with zidovudine plus zalcitabine treatmentreduces the emergence in vivo of zidovudine resistance HIV mutations, J MED VIROL, 57(2), 1999, pp. 163-168
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
Authors: Lechat, P Brunhuber, KW Hofmann, R Kuhn, P Nesser, HJ Slany, J Weihs, W Wiedermann, C Wimmer, H van Mieghem, W Boland, J Chaudron, JM Jordaens, L Melchior, JP Aschermann, M Bruthansl, J Hradec, M Kolbel, F Semrad, B Haghfelt, T Fischer-Hansen, J Goetzsche, CO Hildebrandt, P Kassis, E Rasmussen, V Rokkedal, J Thomassen, A Groundstroem, K Uusimaa, P Le Heuzey, JY Aumont, MC Aupetit, JF Baille, N Baudouy, P Belin, A Bonneau, A Bonneric, G Bousser, JP Citron, B Dary, P Decoulx, E De Groote, P Denolle, T Dievart, F Duriez, P Eicher, JC Enjuto, G Ferriere, M Fournier, E Garandeau, M Gauthier, J Genest, M Gerbe, A Godenir, JP Guillot, B Guillot, JP Guillot, P Heno, P d'Ivernois, C Jean, M Kacet, S Kalle, R Komajda, M Lacroix, A Lallemand, R Lardoux, H Marquet, M Martin, M Martin, O Mery, D Mossaz, R Mothes, P Olive, T Ostorero, M Paganelli, F Page, E Pauly-Laubry, C Puel, J Rousseau, JF Roux, JJ Schenowitz, A Sourdais, K Tremel, F Verdun, A Witchiz, S Wolf, JE Hombach, V Assmann, I Beyer, T Bischoff, KO Darius, H Ertl, G Fleck, E Forster, K Freytag, F Gleichmann, U Haasis, R Henssge, R Hey, D Hesse, P Hofs, T Keck, M Klein, H Kromer, ET Kruls-Munch, J Luderitz, B Maisch, B Mitrovic, V Neubauer, S Osterziel, KJ Simon, H Spitzer, SG Stohring, R Taubert, G Teichmann, W Theisen, K Wende, W Wieser, H Zotz, R Preda, I Csanady, M Cserhalmi, L Edes, I Gesztesi, T Karpati, P Simon, K Tarjan, J Fogari, R Tramarin, R Galie, N Giani, P Milanese, U Scalvini, S Scrutinio, D Sechi, LA Tettamanti, F De Vito, F Crean, P McCann, H Mulcahy, D Sugrue, D van Hoogenhuyze, DCA van der Burgh, PH Ciampricotti, R van Dantzig, JM DenHartog, FR Henneman, JA van Kesteren, HAM Kragten, JA Liem, KL Limburg, A van der Linde, MR Linssen, GCM Pasteuning, H Penn, HJAM Van Rossum, P Schaafsma, HJ Schelling, A Sloos, R Wesdorp, JCL Korewicki, J Achremczyk, P Czestockowska, E Dowgird, M Dyduszynski, A Gorski, J Ilmurzynska, K Janicki, K Kornacewicz-Jach, Z Kraska, T Krzeminska-Pakula, M Kuch, J Nartowicz, E Petelenz, T Piwowarska, W Rawczynska-Englert, I Ruzyllo, W Swiatecka, G Tendera, M Wierzchowiecki, M Wodniecki, J Wojciechowoski, D Wrabec, K Wysocki, H Gomes, RS Ceia, MF Lousada, N Campos, JMM Providencia, LA de Moura, ALZC Marejev, VJ Aronov, DM Arutjunov, GP Bart, BJ Basechikin, SS Belenkov, JN Beloussov, JB Bokeria, OA Charchogljan, RA Doschytsin, V Fedorova, TA Glezer, MG Gorbachenkov, A Gorshkov, VA Gospodarenko, AL Ivashkin, VT Ivleva, AJ Kyrichenko, AA Lavrov, AA Lazebnik, LB Marynov, A Mazaev, VP Polejev, NR Shpektor, A Sidorenko, BA Sobolev, KE Starodoubtsev, AK Storozhakhov, GI Syrkin, AL Zodionchenko, VS Zvereva, TV Murin, J Kaliska, G Rybar, R Valle, V Artaza, M Conthe, P Cruz, JM Garcia-Moll, M Lopez-Sendon, JL Martinez, A Monzon, F Ribas, M Roig, E Roldan, I Hoglund, C Ekdahl, S Hjelmaeus, L Lindberg, K Lofdahl, P Ulvenstam, G Warselius, L Follath, F Anghern, W Dubach, P Erne, P Gallino, A Moccetti, T Bridges, A Adgey, J Ambepitiya, G Boon, N Boyle, RM Cowley, AJ Cripps, T Davies, MK Dunn, F Findlay, J Forsey, P Fyfe, T Gould, B Greenwood, TW Hubner, P Khan, S Lewis, P Mackay, A Maltz, M McArthur, J McLeod, A McLeod, D Metcalfe, M Millar-Craig, M Mills, P Nelson, JK Nicholls, D Oakley, GD Patterson, DLH Pohl, JEF Ray, S Silke, B Wilkinson, PR Jmouro, AV
Citation: P. Lechat et al., The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, LANCET, 353(9146), 1999, pp. 9-13
Angiotensin I-converting enzyme gene polymorphism in a low-risk European population for coronary artery disease
Authors: Ferrieres, J Ruidavets, JB Fauvel, J Perret, B Taraszkiewicz, D Fourcade, J Nieto, M Chap, H Puel, J
Citation: J. Ferrieres et al., Angiotensin I-converting enzyme gene polymorphism in a low-risk European population for coronary artery disease, ATHEROSCLER, 142(1), 1999, pp. 211-216
Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy
Authors: Izopet, J Salama, G Pasquier, C Sandres, K Marchou, B Massip, T Puel, J
Citation: J. Izopet et al., Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy, J ACQ IMM D, 19(5), 1998, pp. 478-483
Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter,controlled, randomized trial
Authors: Payen, JL Izopet, J Galindo-Migeot, V Lauwers-Cances, V Zarski, JP Seigneurin, JM Dussaix, E Voigt, JJ Selves, J Barange, K Puel, J Pascal, JP
Citation: Jl. Payen et al., Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter,controlled, randomized trial, HEPATOLOGY, 28(6), 1998, pp. 1680-1686
Coronary stenting of bifurcation lesions using "T" or "reverse Y" configuration with Wiktor stent
Authors: Carrie, D Elbaz, M Dambrin, G Saint-Cricq, F Dugrand, P Fourcade, J Puel, J
Citation: D. Carrie et al., Coronary stenting of bifurcation lesions using "T" or "reverse Y" configuration with Wiktor stent, AM J CARD, 82(11), 1998, pp. 1418
Risultati: 1-25 | 26-36 |